A recent phase II trial evaluated the efficacy of rusfertide in reducing and controlling hematocrit levels in patients with polycythemia vera (PV) requiring therapeutic phlebotomy (TP). The hepcidin mimetic successfully maintained hematocrit at less than 45% and was well tolerated in the study population. In an abstract presented at the 64th American Society of Hematology Annual Meeting and Exposition, the research team presented the treatment-emergent adverse event (TEAE) profile of the study participants. ...
2022 ASH Annual Meeting & Exposition - Focus on MPN
The 64th American Society of Hematology Annual Meeting and Exposition took place December 10-13 in New Orleans, Louisiana. This year’s meeting featured plenary lectures, expert sessions, poster presentations, and much more. Find highlights from the sessions that are most relevant to oncology nurses, including those with a focus on the latest treatment strategies for myeloproliferative neoplasms (MPN).
Advertisement
Researchers determined the incidence of TEAEs related to rusfertide in patients with PV.
The phase II study results are in. Researchers will now test rusfertide against placebo in a randomized clinical trial.
Researchers evaluated risk factors for ATEs and VTEs. Their scoring system performed better than the current standard.
Do cytoreductive therapies affect quality of life for patients with MPN in different ways?
Patients with MPN who had an AMI are analyzed for risk of additional major adverse cardiovascular events and bleeding.
Advertisement
